# Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury

> **NCT02917291** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ferrer Internacional S.A.** · enrollment: 48 (estimated)

## Conditions studied

- Acute Traumatic Spinal Cord Injury

## Interventions

- **DRUG:** FAB117-HC
- **OTHER:** Control group
- **DRUG:** FAB117-HC

## Key facts

- **NCT ID:** NCT02917291
- **Lead sponsor:** Ferrer Internacional S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2022-07
- **Final completion:** 2023-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02917291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02917291, "Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02917291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*